Skip to main content
Erschienen in: Journal of Neurology 3/2016

01.03.2016 | Original Communication

Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors

verfasst von: Maria Laura Ester Bianchi, Emanuele Leoncini, Marcella Masciullo, Anna Modoni, Shahinaz M. Gadalla, Roberto Massa, Emanuele Rastelli, Chiara Terracciano, Giovanni Antonini, Elisabetta Bucci, Antonio Petrucci, Sandro Costanzi, Massimo Santoro, Stefania Boccia, Gabriella Silvestri

Erschienen in: Journal of Neurology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Recent studies documented an increased risk of neoplasm in patients with myotonic dystrophies (DM). Yet, none of these studies evaluated the contribution of common cancer risk factors in such observation. In this study, we included a cohort of patients (n = 255) with an established molecular diagnosis of DM type 1 (DM1), and who receives their treatment in one of the four centers with recognized expertise in neuromuscular disorders in Rome. We estimated the prevalence of benign and malignant tumors, and assessed if lifestyle factors and/or specific disease features would be associated to their occurrence. Overall, 59 benign tumors in 54 patients and 19 malignant tumors in 17 patients were diagnosed. The most common malignant neoplasms were cancers of the skin (31.6 %), thyroid (21.0 %), ovary (10.5 %), and breast (10.5 %). Uterine fibroid was the most common benign tumor (37.6 %) in women, while pilomatricoma was the most common in men (28.6 %). Age at enrollment (OR = 1.02, 95 % CI 1.00–1.05), and female gender (OR = 5.71, 95 % CI 2.90–11.22) were associated with tumor development in DM1 patients, while thyroid disorders was associated with malignant tumors only in women (OR = 5.12, 95 % CI 1.35–19.37). There was no association between tumor development and evaluated lifestyle factors. In conclusion, the lack of association between common cancer risk factors and tumor development in DM1 support a pathogenic link between tumors and DM1 itself, emphasizing the need for a systematic surveillance. Our observation of an association between thyroid diseases in women and cancer development needs confirmation.
Literatur
1.
Zurück zum Zitat Ashizawa T, Sarkar PS (2011) Myotonic dystrophy types 1 and 2. Handb Clin Neurol 101:193–237CrossRefPubMed Ashizawa T, Sarkar PS (2011) Myotonic dystrophy types 1 and 2. Handb Clin Neurol 101:193–237CrossRefPubMed
2.
Zurück zum Zitat PS Harper (2001) Myotonic Dystrophy, 3rd edn. London PS Harper (2001) Myotonic Dystrophy, 3rd edn. London
3.
Zurück zum Zitat Cantwell AR Jr, Reed WB (1965) Myotonia atrophica and multiple calcifying epithelioma of Malherbe. Acta Derm Venereol 45:387–390PubMed Cantwell AR Jr, Reed WB (1965) Myotonia atrophica and multiple calcifying epithelioma of Malherbe. Acta Derm Venereol 45:387–390PubMed
4.
Zurück zum Zitat Street ML, Rogers RS 3rd (1991) Multiple pilomatricomas and myotonic dystrophy. J Dermatol Surg Oncol 17:728–730CrossRefPubMed Street ML, Rogers RS 3rd (1991) Multiple pilomatricomas and myotonic dystrophy. J Dermatol Surg Oncol 17:728–730CrossRefPubMed
5.
Zurück zum Zitat Laredo Ortiz C, Munoz Romero F, Mallent Anon J, Domenech Miro E, Tafalla Pena M (1997) Multiple pilomatrixomas associated with Steinert disease. An Med Interna 14:409–411PubMed Laredo Ortiz C, Munoz Romero F, Mallent Anon J, Domenech Miro E, Tafalla Pena M (1997) Multiple pilomatrixomas associated with Steinert disease. An Med Interna 14:409–411PubMed
6.
Zurück zum Zitat Barberio E, Nino M, Dente V, Delfino M (2002) Guess what! Multiple pilomatricomas and Steiner disease. Eur J Dermatol 12:293–294PubMed Barberio E, Nino M, Dente V, Delfino M (2002) Guess what! Multiple pilomatricomas and Steiner disease. Eur J Dermatol 12:293–294PubMed
7.
Zurück zum Zitat Gadalla SM, Lund M, Pfeiffer RM, Gørtz S, Mueller CM, Moxley RT 3rd, Kristinsson SY, Björkholm M, Shebl FM, Hilbert JE, Landgren O, Wohlfahrt J, Melbye M, Greene MH (2011) Cancer risk among patients with myotonic muscular dystrophy. JAMA 306:2480–2486CrossRefPubMedPubMedCentral Gadalla SM, Lund M, Pfeiffer RM, Gørtz S, Mueller CM, Moxley RT 3rd, Kristinsson SY, Björkholm M, Shebl FM, Hilbert JE, Landgren O, Wohlfahrt J, Melbye M, Greene MH (2011) Cancer risk among patients with myotonic muscular dystrophy. JAMA 306:2480–2486CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Mohamed S, Pruna L, Kaminsky P (2013) Increasing risk of tumors in myotonic dystrophy type 1. Presse Med 42:281–284CrossRef Mohamed S, Pruna L, Kaminsky P (2013) Increasing risk of tumors in myotonic dystrophy type 1. Presse Med 42:281–284CrossRef
10.
Zurück zum Zitat Das M, Moxley RT 3rd, Hilbert JE, Martens WB, Letren L, Greene MH, Gadalla SM (2012) Correlates of tumor development in patients with myotonic dystrophy. J Neurol 259:2161–2166CrossRefPubMedPubMedCentral Das M, Moxley RT 3rd, Hilbert JE, Martens WB, Letren L, Greene MH, Gadalla SM (2012) Correlates of tumor development in patients with myotonic dystrophy. J Neurol 259:2161–2166CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Gennarelli M, Pavoni M, Amicucci P, Novelli G, Dallapiccola B (1998) A single polymerase chain reaction-based protocol for detecting normal and expanded alleles in myotonic dystrophy. Diagn Mol Pathol 7:135–137CrossRefPubMed Gennarelli M, Pavoni M, Amicucci P, Novelli G, Dallapiccola B (1998) A single polymerase chain reaction-based protocol for detecting normal and expanded alleles in myotonic dystrophy. Diagn Mol Pathol 7:135–137CrossRefPubMed
12.
Zurück zum Zitat Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C (2004) Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 61:1943–1947PubMed Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C (2004) Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 61:1943–1947PubMed
13.
Zurück zum Zitat [No authors listed] New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC) (2000) Neurology 54:1218-21 [No authors listed] New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC) (2000) Neurology 54:1218-21
14.
Zurück zum Zitat AIRTUM Working group (2011) Italian cancer figures, report 2011: survival of cancer patients in Italy. Epidemiol Prev 35:1–200 AIRTUM Working group (2011) Italian cancer figures, report 2011: survival of cancer patients in Italy. Epidemiol Prev 35:1–200
15.
Zurück zum Zitat Gadalla SM, Pfeiffer RM, Kristinsson SY, Björkholm M, Hilbert JE, Moxley RT 3rd, Landgren O, Greene MH (2013) Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis. PLoS ONE 8:e79851CrossRefPubMedPubMedCentral Gadalla SM, Pfeiffer RM, Kristinsson SY, Björkholm M, Hilbert JE, Moxley RT 3rd, Landgren O, Greene MH (2013) Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis. PLoS ONE 8:e79851CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Okolo S (2008) Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 22:571–588CrossRefPubMed Okolo S (2008) Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 22:571–588CrossRefPubMed
17.
Zurück zum Zitat Lund M, Diaz LJ, Gørtz S, Feenstra B, Duno M, Juncker I, Eiberg H, Vissing J, Wohlfahrt J, Melbye M (2014) Risk of cancer in relatives of patients with myotonic dystrophy: a population-based cohort study. Eur J Neurol 21:1192–1197CrossRefPubMed Lund M, Diaz LJ, Gørtz S, Feenstra B, Duno M, Juncker I, Eiberg H, Vissing J, Wohlfahrt J, Melbye M (2014) Risk of cancer in relatives of patients with myotonic dystrophy: a population-based cohort study. Eur J Neurol 21:1192–1197CrossRefPubMed
18.
Zurück zum Zitat Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11:891–905CrossRefPubMed Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11:891–905CrossRefPubMed
20.
Zurück zum Zitat Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT 3rd, Greene MH (2009) Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 20:2009–2020CrossRefPubMedPubMedCentral Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT 3rd, Greene MH (2009) Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 20:2009–2020CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Santoro M, Masciullo M, Bonvissuto D, Bianchi ML, Michetti F, Silvestri G (2013) Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2. Mol Cell Biochem 380:259–265CrossRefPubMed Santoro M, Masciullo M, Bonvissuto D, Bianchi ML, Michetti F, Silvestri G (2013) Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2. Mol Cell Biochem 380:259–265CrossRefPubMed
22.
Zurück zum Zitat Belfiore A, Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18:R125–R147CrossRefPubMed Belfiore A, Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18:R125–R147CrossRefPubMed
23.
Zurück zum Zitat Perbellini R, Greco S, Sarra-Ferraris G, Cardani R, Capogrossi MC, Meola G, Martelli F (2011) Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord 21:81–88CrossRefPubMed Perbellini R, Greco S, Sarra-Ferraris G, Cardani R, Capogrossi MC, Meola G, Martelli F (2011) Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord 21:81–88CrossRefPubMed
24.
Zurück zum Zitat Cheng Q, Yi B, Wang A, Jiang X (2013) Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Onco Targets Ther 6:1675–1684PubMedPubMedCentral Cheng Q, Yi B, Wang A, Jiang X (2013) Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Onco Targets Ther 6:1675–1684PubMedPubMedCentral
25.
Zurück zum Zitat Pallante P, Battista S, Pierantoni GM, Fusco A (2014) Deregulation of microRNA expression in thyroid neoplasias. Nat Rev Endocrinol 10:88–101CrossRefPubMed Pallante P, Battista S, Pierantoni GM, Fusco A (2014) Deregulation of microRNA expression in thyroid neoplasias. Nat Rev Endocrinol 10:88–101CrossRefPubMed
26.
Zurück zum Zitat Schuler S, Ponnath M, Engel J, Ortmann O (2013) Ovarian epithelial tumors and reproductive factors:a systematic review. Arch Gynecol Obstet 287:1187–1204CrossRefPubMed Schuler S, Ponnath M, Engel J, Ortmann O (2013) Ovarian epithelial tumors and reproductive factors:a systematic review. Arch Gynecol Obstet 287:1187–1204CrossRefPubMed
27.
Zurück zum Zitat Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144:1–10CrossRefPubMedPubMedCentral Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144:1–10CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Ørngreen MC, Arlien-Søborg P, Duno M, Hertz JM, Vissing J (2012) Endocrine function in 97 patients with myotonic dystrophy type 1. J Neurol 259:912–920CrossRefPubMed Ørngreen MC, Arlien-Søborg P, Duno M, Hertz JM, Vissing J (2012) Endocrine function in 97 patients with myotonic dystrophy type 1. J Neurol 259:912–920CrossRefPubMed
30.
Zurück zum Zitat Srebnik N, Margalioth EJ, Rabinowitz R, Varshaver I, Altarescu G, Renbaum P, Levi-Lahad E, Weintraub A, Eldar-Geva T (2014) Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy. Reprod Biomed Online 29:94–101CrossRefPubMed Srebnik N, Margalioth EJ, Rabinowitz R, Varshaver I, Altarescu G, Renbaum P, Levi-Lahad E, Weintraub A, Eldar-Geva T (2014) Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy. Reprod Biomed Online 29:94–101CrossRefPubMed
Metadaten
Titel
Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors
verfasst von
Maria Laura Ester Bianchi
Emanuele Leoncini
Marcella Masciullo
Anna Modoni
Shahinaz M. Gadalla
Roberto Massa
Emanuele Rastelli
Chiara Terracciano
Giovanni Antonini
Elisabetta Bucci
Antonio Petrucci
Sandro Costanzi
Massimo Santoro
Stefania Boccia
Gabriella Silvestri
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 3/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-8006-y

Weitere Artikel der Ausgabe 3/2016

Journal of Neurology 3/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.